Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Haeyoung KimYeon Jeong KimDonghyun ParkWoong-Yang ParkDoo Ho ChoiWon ParkWon Kyung ChoNalee KimPublished in: Breast cancer research and treatment (2021)
Among patients with post-NAC residual TNBC, more than a quarter exhibited a detectable amount of ctDNA after curative surgery. The ctDNA VAF changed variably during the course of PORT. Therefore, ctDNA kinetics can serve as a biomarker for optimizing adjuvant treatment.
Keyphrases
- circulating tumor
- neoadjuvant chemotherapy
- locally advanced
- circulating tumor cells
- cell free
- rectal cancer
- early stage
- sentinel lymph node
- lymph node
- minimally invasive
- squamous cell carcinoma
- coronary artery bypass
- patients undergoing
- transcription factor
- coronary artery disease
- atrial fibrillation
- single molecule